Skip to main content
Sign In

Search

Search for a Specific Type of Clinical Trial
Note: This page will take a moment to download because of the quantity of trials.

Feedback

Did you have problems using this page? Please fill out our Feedback Form

Clinical Trials

Volunteer to Be Part of a Research Study

Page through all School of Medicine clinical and research trials below. There are two categories:

  • Detailed Trial Descriptions, submitted by researchers, includes trial specifics and contact information.

  • Additional Clinical Trials, which include basic study details. To contact the researcher either Google the PI (primary investigator) name or use our campus directory.

If you are a researcher seeking volunteers and your study is not posted, please
submit your Web ad here.
  

Detailed Trial Descriptions

 Results From Research and Clinical Trials : Selected site
Data pager
<
>
Page Size
PageSizeComboBox
select
 |  Displaying page 1 of 5, items 1 to 30 of 131.
TitleStudy GoalsEligibility CriteriaContact Information
Data pager
<
>
Page Size
PageSizeComboBox
select
 |  Displaying page 1 of 5, items 1 to 30 of 131.
Do you have Parkinson's Disease? 11-1237
To explore the effects of different doses of endurance exercise in people with PD.​
Persons 40-80 who have been diagnosed with Parkinson's Disease and are not yet taking medication or plant to start medication within the next 6 months. You must be willing to begin the exercise program immediately or after a delay of 6 months and willing to do aerobic exercise on a treadmill.
PI: Schenkman, Margaret
  • 720-848-6376
  • Toby.Wellington@ucdenver.edu
Do you have Atopic Dermatitis (Eczema)? HS-2581
To study eczema
Males and Females between 3 and 80 who have atopic dermatitis or males and females between 8 months and 80 who have a history of, or an active case of eczema hereticum (wide-spread herpes skin infection along with atopic dermatitis.
PI: Leung, Donald
  • 303-398-1409
  • taylorp@njhealth.org
Better Control of Type 2 Diabetes May Decrease Your Risk for Cardiovascular Disease. 10-0644
To look at the use of an extended release formula of Exenatide compared to a placebo to maintain normal glucose levels. Ultimately to see better control of diabetes and a decrease in cardiovascular disease events.​
Person 18+ with Type 2 Diabetes and take no more than 2 diabetes medications with stale doses for the last 3 months. Must not have a planned or anticipated revascularization procedure, but may have a history of cardiovascular disease and must see your primary care physician at least twice a year.
PI: Rasouli, Neda
  • 303-399-8020 X2059
  • chantal.underkofler@ucdenver.edu
Type 2 Diabetes and Exercise Research Study 10-1393
To research the effects of an investigational drug on exercise capacity and blood vessel function​.​
Person 30-60 with Type 2 diabetes who exercise vigorously less than one hour per week and have normal blood pressure. Must not have smoked for at least one year and have a BMI between 25-39.9.
PI: Schauer, Irene
  • 720-848-6688
  • Katie.Rogers@ucdenver.edu
Are you a Non-smoking Adult between the ages of 45 and 85? HS-1883a
We are interested in learning more about smoking related lung disease, and need healthy non-smoking participants.
45-85 years old Non-Hispanic White or African American No smoking history No evidence of lung disease
PI: Bowler, Russ
  • 303-270-2566
  • FratelliC@NJHealth.org
Alterations in Lung Microbiome in Acute and Chronic HIV Infection 09-0898
This is a prospective, observational cohort study. Three groups (A1, A2, and B) will be enrolled in parallel.
-Men and women >/= 18 years. -Willing to follow all research requirements -Willing to provide written informed consent -Group A1- acute HIV infection defined as a high risk HIV exposure within the prior 30 days, or recent HIV-1 seroconversion defined as those with a high risk HIV-1 exposure -Group A2- healthy controls: HIV-1 seronegative with no high risk HIV-1 exposure in the prior 30 days and no chronic medical illness -Group B- HIV-1 infection diagnosed by a previous positive antibody or PCR test have been recommended to initiate HAART by their health care provider You should not be in this study if you are a pregnant or planning to become pregnant.
PI: Campbell, Thomas
  • 303-724-0762
  • christine.griesmer@ucdenver.edu
Has your child been diagnosed with generalized anxiety disorder? 13-1967
to study sleep and brain activity
• between the ages of 12 & 18 • diagnosed with GAD OR • not diagnosed with any psychological disorders AND who are • right-handed • without orthodontic braces • not taking sleep medications
PI: Mullin, Benjamin
  • 720-777-8006
  • benjamin.mullin@ucdenver.edu
Volunteers needed to Participate in a Research Study about Rheumatoid Arthritis 01-675
The purpose of this study is to learn more about how rheumatoid arthritis develops by studying people who do not have rheumatoid arthritis. Your participation in this study will help us determine if certain genetic and environmental factors affect the chances of developing RA-related autoantibodies in absence of rheumatoid arthritis.
You may be eligible to participate in the study if: -You are at least 40 years old -You do NOT have Rheumatoid Arthritis (RA)
PI: Norris, Jill
  • 303-724-7510
  • Marie.Feser@ucdenver.edu
Restoring Insulin Secretion (RISE) 13-0122
The Children’s Hospital Colorado Clinical Translational Research Center and the National Institutes of Health are conducting a study. This study is aimed at testing whether early treatment is beneficial to kids with early type 2 diabetes and kids at high risk of diabetes.
10-19 years of age, Pubertal, Overweight, Fasting glucose: >90 mg/dl; Impaired glucose tolerance: >140 mg/dl; Pre-diabetes or diagnosed with diabetes for less than 6 months; Metformin
PI: Nadeau, Kristen
  • Susan Gross
  • susan.gross@childrenscolorado.edu
Have you experienced a preterm birth? 13-0409
If you participate, the information we learn from you will help us better understand how and why 1 out of 10 pregnancies in the US end in preterm birth.
1. Women ages 18-45 years old 2. willing to meet for 1-2 hours in a focus group setting 3. a mother of a baby who was born more than 3 weeks before your due date
PI: Santoro, Nanette
  • 303-724-2046
  • celeste.robledo@ucdenver.edu
Do You Smoke? 12-0181
To figure out how these lung substances work in people who drink too much alcohol, who usually smoke, compared to those who do not drink heavily, but who smoke.
Smoking and nonsmoking males
PI: Burnham, Ellen
  • 303-724-6081
  • Carrie.Higgins@ucdenver.edu
Parents or Legal Guardians of Children with Disabilities 12-1664
Assistive Technology Partners, University of Colorado, Anschutz Medical Campus, is performing a study investigating the impact Socially Assistive Robotics has on motor, communication and cognitive skills of children with disabilities.
Children between the ages of 18 months to 5 years of age Have Significant motor and communication disabilities/delays NOT been diagnosed with blindness or deafness They are without a seizure disorder or with a well-controlled seizure disorder They have been on stable medication regime for the past 12 weeks, if they are currently taking medication.
PI: Sandstrum, Jim
  • 303-315-1287
  • Jim.Sandstrum@ucdenver.edu
The Influence of Couples' Conversation on the Heart 13-2188
The purpose of the study is to examine the influence that conversations between married couples have on the functioning of the heart.
Married Christian couples who: • Have been married for at least 1 yr. • Both believe in prayer. • Are not currently taking heart medications. • Do not have heart problems. • Are not pregnant.
PI: Grigsby, Megan
  • 303-556-6020
  • couplesandheartstudy@gmail.com
Help Us Learn About Schizophrenia! 12-1186
Help us learn more about a new drug that may improve thinking and concentration in people with schizophrenia.
We are looking for: Male and female adults who smoke 18-50 years old No previous or current mental illness No drug use Willing to use nicotine patch during study hospital visit If female, willing to use birth control during the study
PI: Freedman, Robert
  • 303-724-6214 or 303-724-7373
  • psypharmresearch@ucdenver.edu
Do you use just a rescue inhaler for asthma treatment? 29167/38
Researchers are studying an investigational medication for the treatment of asthma in adults.
Qualifications include: 18-75 years old with asthma Use only a rescue inhaler for asthma treatment
PI: Katial, Rohit
  • 303-398-1966
  • currierh@njhealth.org
Exercise for Healthy Aging 14-2207
We need HIV+ and HIV- men and women ages 50-70 who are not currently exercising to join a 6 month exercise program
- HIV+ or HIV- - Aged 50-70 - < 2 days/week of cardiovascular or strength training over the past 6 months - Be willing to come into the Research Center at least 3 days per week for 6 months for supervised exercise training - For women, must be post-menopausal - Body mass index between 20 and 39 - Persons with the following would not be eligible: diabetes; persistent blood pressure >180/100; lung disease requiring 4 or more liters of oxygen with exercise; cancer within 1 year of enrollment; surgery or injury within 6 months of enrollment that would impact an ability to exercise; unstable heart disease; severe liver disease; prior impairment from a stroke or ongoing problems from bone or joint disease that would limit the ability to exercise; moderate to severe dementia. - Persons taking the following medications would NOT be eligible: corticosteroid medications (such as prednisone) by mouth or injection; growth hormone or growth hormone-like therapy (ex: tesamorelin); estrogens; testosterone by injection (patch or gel is ok); chemotherapy - If hepatitis B or C positive, must have an undetectable viral load - If HIV+, must be on antiretroviral therapy for at least 2 years with a mostly undetectable HIV viral load, and no viral load more than 200 copies - If HIV+, must have a CD4 count greater than 200 cells and no AIDS-associated injections in the last 6 months
PI: Erlandson, Kristine
  • 303-724-4941
  • kristine.erlandson@ucdenver.edu
Research Trial Evaluating a New Drug in Psoriasis: Now Enrolling 14-1692
The study will evaluate an investigational drug compared to a currently approved psoriasis medication. Your participation will provide valuable information to researchers seeking new and improved therapies. You will be given either Humira, placebo, or the investigational drug for up to 28 weeks, after which you may be switched over to the active drug depending on your response.
You may be eligible to participate if 18 years of age or older and have been diagnosed with moderate to severe plaque-type psoriasis for at least 6 months.
PI: Armstrong, April
  • 720-848-3607
  • psoriasiscolorado@ucdenver.edu
Participants with Chronic Kidney Disease and Vitamin D Deficiency Needed for a Research Study 11-0521
This study will examine whether nutritional or active vitamin D supplementation will improve blood vessel function​.
Person 18-80 with chronic kidney disease stage 3B or 4 (estimated GFR 44-15 m;/min) with a vitamin D deficiency or insufficiency.  Women must not be pregnant or breastfeeding.
PI: Kendrick, Jessica
  • 303-724-2275
  • Emily.Decker@ucdenver.edu
Trouble Sleeping? HS-2655
Study the effects of two different study drugs, one or two non-drug interventions and/or a combination of both to treat insomnia.
Persons 21+ who have trouble falling or staying asleep at night.
PI: Edinger, Jack
  • 303-398-1938
  • DepewA@njhealth.org
MS Volunteers Needed for Research Study 12-1388
Looking to see if there is a cognitive improvement with the treatment of oral estriol as compared to oral placebo.
We are looking for: • Women 18-50 years old • Diagnosed with definite relapsing-remitting, secondary-progressive multiple sclerosis or primary-progressive multiple sclerosis • MS disease duration of 15 years or less • On stable dose of standard MS treatment with Copaxone®, Betaseron® (or Extavia®), Rebif®,Avonex®, Gilenya®, Aubagio®, Tecfidera®, or no treatment ----You are not eligible for the study if you are pregnant, breast-feeding, smoke, or have other serious medical conditions.
PI: Corboy, John
  • Brittany Kling
  • Brittany.Kling@ucdenver.edu
Give Us a Hand 12-1084
To better understand Multiple Sclerosis in children and teens.
Between the ages of 3-20 AND have Multiple Sclerosis diagnosed before 18 OR Do not have MS
PI: Schreiner, Teri
  • 303-724-3635
  • kathryn.connelly@ucdenver.edu
Are you an African American with asthma? HS-2805
 We are studying why some African American people have trouble with their asthma despite taking asthma medications.
 Children age 5-17 and non-smoking Adults age18 and older who have asthma symptoms despite asthma treatment • African American ancestry (have at least one    African American grandparent)
PI: Wechsler, MD, Michael
  • 303-398-1443
  • martinlab@njhealth.org
Peanut and Tree-Nut Allergy Research Study 13-2102
The purpose of this study is to determine how the body's immune system interacts with nuts and other foods to cause allergic reaction.
6-75 years of age. Have a diagnosis of peanut and/or tree-nut allergy made by either skin test or blood tests. Have no known peanut and/or tree-nut allergy.
PI: Dreskin, Stephen
  • 303-724-7193
  • Spodra.Eglite@ucdenver.edu
Research about the Effect of Carbamazepine medication on the Etonogestrel Contraceptive Implant (Implanon®/Nexplanon®) 14-0584
Do you currently have a birth control implant (Implanon®/ Nexplanon®) and are interested in participating in a research study to better understand the effects of certain medication on the implant?
Women ages 18-45 who have had a birth control implant 1 to 3 years • Do not take any medications that are known to effect liver enzymes • Be willing to abstain during the study period or use a secondary form of non-hormonal contraception • Have baseline systolic blood pressure
PI: Lazorwitz, Aaron
  • 303-724-8482
  • maryke.swartz@ucdenver.edu
Do you have human growth hormone (hGH) deficiency? 13-2629
Primary: To demonstrate a clinical superiority of MOD-4023 over placebo in terms of decrease in Fat Mass (FM) in adult subjects with Growth Hormone Deficiency Secondary a. To determine the efficacy of MOD-4023 over placebo in other body composition variables (such as lean body mass and waist-to-hip ratio) b. To evaluate the safety and tolerability of MOD-4023 over placebo in adult subjects with GHD c. To determine the IGF-I and IGFBP-3 serum levels
Adult men and women aged 23 to 70 years of age diagnosed with either adult or childhood onset growth hormone deficiency (GHD).
PI: Wierman, Margaret
  • 720-848-7710
  • Shannon.Moore@ucdenver.edu
Are you a parent of a child with a developmental disability and willing to contribute to a research project to increase awareness and understanding? 14-1287
The purpose of this study is to gain knowledge on the topic of everyday stressors that affect the lives of children with developmental disabilities, as well as their parents/caregivers
Are you a parent of a child with a developmental disability and willing to contribute to a research project to increase awareness and understanding?
PI: Benson, Brenna
  • (303) 520-7346
  • brenna.benson@ucdenver.edu
Healthy Female Adults Needed!!! 07-0816
For brain imaging research study on how the brain works with we taste sweets. Your participation could help us to develop treatments and preventive measures for anorexia nervosa and obesity
Healthy females 22 to 29 who are right-handed, free of medication with no serious medical conditions, permanent metal implants or braces/retainers, and are at a healthy body weight.
PI: Frank, Guido
  • 720-777-4026
  • imaging.research@childrenscolorado.org
Healthy Volunteers Needed for a Research Study on Kidney Disease 14-1209
To understand whether patients with kidney disease with or without a kidney transplant have high levels of microparticles compared to healthy adults. Microparticles are small vesicles that our cells release in response to injury.
Healthy individuals 18 and older. *If you have diabetes, high blood pressure, or heart disease you will not qualify for the study. Pregnant and lactating women are not eligible.
PI: Thurman, Joshua
  • 303-724-8781
  • Karissa Fetrow
Do you have an egg allergy? HS-2764
To see if taking Baked Egg Therapy vs. Oral Immunotherapy may help egg-allergic children tolerate eggs.
males and females 3 to 16 years old, with documented egg allergy, ability to make regular visits to National Jewish Health for up to 2 years.
PI: Leung, Donald
  • 303-398-1618
  • ReamesR@NJHealth.org
Are you interested in Weight Loss? 13-1550
Volunteers needed for a research study to determine the best time to begin exercise within a lifestyle weight loss program.
• Be between 18 and 55 years old • Be generally healthy without diabetes or heart disease • Be a non-smoker • Not currently exercising regularly • Have a BMI between 28 and 40 kg/m2 (check your BMI at: http://www.nhlbisupport.com/bmi/)
PI: Catenacci, Victoria
  • 303-724-9098
  • kristen.bing@ucdenver.edu

​Additional Clinical Trails

 Results From Research : Selected site
Data pager
<
>
Page Size
PageSizeComboBox
select
 |  Displaying page 1 of 19, items 1 to 30 of 549.
Protocol TitlePI NameInstitution Number
Data pager
<
>
Page Size
PageSizeComboBox
select
 |  Displaying page 1 of 19, items 1 to 30 of 549.
NSABP B-31 A RANDOMIZED TRIAL COMPARING THE SAFETY AND EFFICACY OF ADRIAMYCIN AND CYCLOPHOSPHAMIDE FOLLOWED BY TAXOL (AC-T) TO THAT OF ADRIAMYCIN AND CYCLOPHOSPHAMIDE FOLLOWED BY TAXOL PLUS HERCEPTIN (AC-T+H) IN NODE-POSITIVE BREAST CANCER PATIENTS WHO HAVE TUMORS THAT OVEREXPRESS HER2
Nicole, Kounalakis00-236
SWOG N9831 PHASE III TRIAL OF DOXORUBICIN AND CYCLOPHOSPHAMIDE (AC) FOLLOWED BY WEEKLY PACLITAXEL WITH OR WITHOUT TRASTUZUMAB AS ADJUVANT TREATMENT FOR WOMEN WITH HER-2 OVEREXPRESSING NODE POSITIVE OR HIGH-RISK NODE NEGATIVE BREAST CANCER
Anthony, Elias00-954
PACTG 1020-A, PHASE I/II OPEN LABEL PHARMACOKINETIC AND SAFETY STUDY OF A NOVEL PROTEASE INHIBITOR (BMS 232632) IN COMBINATION REGIMENS IN ART NAIVE AND EXPERIENCED HIV-INFECTED INFANTS, CHILDREN AND ADOLESCENTS. Version 6
Elizabeth, McFarland00-958
GOG#184 - A RANDOMIZED PHASE III STUDY OF TUMOR VOLUME DIRECTED PELVIC PLUS OR MINUS PARA-AORTIC IRRADIATION FOLLOWED BY CISPLATIN AND DOXORUBICIN OR CISPLATIN, DOXORUBICIN AND PACLITAXEL FOR ADVANCED ENDOMETRIAL CARCINOMA
Saketh, Guntupalli01-101
A RANDOMIZED PHASE II CHEMOPREVENTION STUDY OF ILOPROST VERSUS PLACEBO IN PATIENTS AT HIGH RISK FOR LUNG CANCER
Robert, Keith01-279
A STUDY OF THE EFFECTIVENESS AND TOLERABILITY OF WEEKLY RIFAPENTINE/ISONIAZID FOR THREE MONTHS VERSUS DAILY ISONIAZID FOR NINE MONTHS FOR THE TREATMENT OF LATENT TUBERCULOSIS INFECTION [TBTC STUDY 26]
Edward, Gardner01-284
AUTOLOGOUS PAP-LOADED DENDRITIC CELL VACCINE (APC 8015, PROVENGE) IN PATIENTS WITH NON-METASTATIC PROSTATE CANCER WHO EXPERIENCE PSA ELEVATION FOLLOWING RADICAL PROSTATECTOMY IN RANDOMIZED, CONTROLLED, DOUBLE-BLIND TRIAL
Michael, Glode01-348
CHOLESTEROL AND ANTIOXIDANT TREATMENT IN PATIENTS WITH THE SMITH-LEMLI-OPITZ SYNDROME (SLOS)
Ellen, Elias01-410
A PHASE II STUDY OF ADJUVANT STI571 (GLEEVEC) THERAPY IN PATIENTS FOLLOWING COMPLETELY RESECTED HIGH-RISK PRIMARY GASTROINTESTINAL STROMAL TUMOR (GIST)
Martin, McCarter01-879
ANBL0032 PHASE III RANDOMIZED STUDY OF CHIMERIC ANTIBODY 14.18 (CH 14.18) IN HIGH RISK NEUROBLASTOMA FOLLOWING MYELOABLATIVE THERAPY AND AUTOLOGOUS STEM CELL RESCUE
Brian, Greffe01-932
RTOG 96-01 A PHASE III TRIAL OF RADIATION THERAPY WITH OR WITHOUT CASODEX IN PATIENTS WITH PSA ELEVATION FOLLOWING RADICAL PROSTATECTOMY FOR PT3NO CARCINOMA OF THE PROSTATE.
Rachel, Rabinovitch02-182
DIABETES PREVENTION PROGRAM OUTCOMES STUDY (DPPOS)
Dana, Dabelea02-498
ACOSOG Z9001: A PHASE III RANDOMIZED DOUBLE-BLIND STUDY OF ADJUVANT STI571 (GLEEVEC) VERSUS PLACEBO IN PATIENTS FOLLOWING THE RESECTION OF PRIMARY GASTROINTESTINAL STROMAL TUMOR (GIST)
Martin, McCarter02-607
EFFICACY OF AGGRESSIVE RENIN-ANGIOTENSIN-ALDOSTERONE AXIS BLOCKADE IN PREVENTING/SLOWING RENAL FUNCTION DECLINE IN ADPKD
Robert, Schrier02-744
RANDOMIZED EVALUATION OF RECURRENT STROKE COMPARING PFO CLOSURE TO ESTABLISHED CURRENT STANDARD OF CARE TREATMENT - RESPECT TRIAL
Clark, Anderson02-805
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER PHASE III STUDY COMPARING GW572016 AND LETROZOLE VERSUS LETROZOLE IN SUBJECTS WITH ESTROGEN/PROGESTERONE RECEPTOR-POSITIVE ADVANCED OR METASTATIC BREAST CANCER (EGF 30008).
Anthony, Elias03-1030
A CONTINUATION PROTOCOL FOR PI-88 IN PATIENTS WITH ADVANCED MALIGNANCIES
Sue, Eckhardt03-1250
AALL0031 A CHILDREN'S ONCOLOGY GROUP PILOT STUDY FOR THE TREATMENT OF VERY HIGH RISK ACUTE LYMPHOBLASTIC LEUKEMIA IN CHILDREN AND ADOLESCENTS
Roger, Giller03-239
IMPAACT P1026s: Pharmacokinetic Properties of Antiretroviral and Related Drugs During Pregnancy and Postpartum, Version 9.0
Elizabeth, McFarland03-546
PROSPECTIVE MULTICENTER EVALUATION OF THE DURATION OF THERAPY FOR THROMBOSIS IN CHILDREN
Michael, Wang03-585
TREATMENT OPTIONS FOR TYPE 2 DIABETES IN ADOLESCENTS AND YOUTH
Philip, Zeitler03-595
AHOD0031, A PHASE III GROUP-WIDE STUDY OF DOSE-INTENSIVE RESPONSE-BASED CHEMOTHERAPY AND RADIATION THERAPY FOR CHILDREN AND ADOLESCENTS WITH NEWLY DIAGNOSED INTERMEDIATE RISK HODGKIN DISEASE
Timothy, Garrington03-683
COLORECTAL CHEMOPREVENTION WITH CALCIUM AND VITAMIN D (THE VITAMIN D/CALCIUM POLYP PREVENTION STUDY)
Dennis, Ahnen03-993
CLINICAL CORRELATION AND COST ANALYSIS OF SICKLE CELL PATIENTS UNDERGOING CHRONIC ERYTHROCYTAPHERESES.
Kathryn, Hassell04-0005
A PHASE II MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF 500 MG OF FULVESTRANT (FASLODEX) AS A FIRST LINE HORMONAL TREATMENT IN POSTMENOPAUSAL WOMEN WITH HORMONE RECEPTOR POSITIVE METASTATIC BREAST CANCER.
Virginia, Borges04-0303
Use Of 3,4-Diaminopyridine (3,4-Dap)In The Treatment Of Lambert-Eaton Syndrome (Lems)
Steven, Ringel04-0567
MET FULLY IMPLANTABLE OSSICULAR STIMULATOR
Herman, Jenkins04-0579
ACNS0331: A STUDY EVALUATING LIMITED TARGET VOLUME BOOST IRRADIATION AND REDUCED DOSE CRANIOSPINAL RADIOTHERAPY (18.00 GY) AND CHEMOTHERAPY IN CHILDREN WITH NEWLY DIAGNOSED STANDARD RISK MEDULLOBLASTOMA: A PHASE III DOUBLE RANDOMIZED TRIAL
Nicholas, Foreman04-0625
DOUBLE-BLIND TRIAL OF CHOLINE DURING PREGNANCY AND RISK FOR SCHIZOPHRENIA
Randal, Ross04-0678
A STUDY OF THE EVALVE CARDIOVASCULAR VALVE REPAIR SYSTEM (CVRS) ENDOVASCULAR VALVE EDGE-TO-EDGE REPAIR STUDY
John, Carroll04-0831


Contact Us

Building 500 - 13001 E. 17th Place, Campus Box C290, Aurora, CO 80045

Learn more